Graftskin data show improved wound healing:
This article was originally published in Clinica
Executive Summary
Organogenesis has moved closer to submission for US approval of its Graftskin human skin product after presenting analysis of trial data. Results from the prospective, randomised trial presented at the Symposium on Advanced Woundcare in San Diego this month, show that Graftskin was 60% more effective than standard compression in closing wounds completely in a median time of 57 days compared with 181 for compression. The company is completing analysis of secondary endpoints, including factors such as oedema, pain and exudate, in preparation for a submission for marketing approval.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.